Search Results for: covid-19
GigaGen Announces Publication of Research Describing a New Class of Drugs, Recombinant Hyperimmunes, Including its Novel COVID-19 Therapy, GIGA-2050 August 12, 2020
GigaGen presents a novel technology for producing a new class of drug, which it calls recombinant hyperimmunes…..
RedHill Biopharma Ltd. recently announced approval from the Mexican Federal Committee for the Protection against Sanitary Risks (COFEPRIS) for the company’s Clinical Trial Authorization (CTA) application for….
Cost of Disrupted Clinical Research Due to COVID-19 Equates to $10+ Billion & Potential Study Delays July 22, 2020
What if you developed a potential cure for COVID-19, but couldn’t test the drug because of COVID-19? Thousands of researchers worldwide are facing this dilemma, as clinical studies are interrupted, altered, postponed – or even cancelled…
SGS Joins Biophytis to Launch International Clinical Trial of COVID-19-Related Respiratory Failure Treatment July 7, 2020
SGS has recently received approval from Belgium’s Federal Agency for Medicines and Health Products (FAMHP) and has initiated the first site to begin a new clinical trial of….
The COVID-19 pandemic has led to temporarily increased drug sales for biggest bio/pharma companies in the first quarter (Q1) of 2020. This increase over sales forecasts….
RedHill Biopharma Ltd. recently announced that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved the company’s Clinical Trial Authorization (CTA) application to commence a….
Moderna & Catalent Announce Collaboration for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate June 25, 2020
Moderna, Inc. and Catalent, Inc. recently announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate…..
The CEOs of Gerresheimer, Stevanato Group, and SCHOTT are committed to ensuring ample supply of pharmaceutical containers for any Covid-19 vaccine and treatment that is developed, and that no patient shall be left….
Catalent, Inc. recently announced that Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca PLC at Catalent’s manufacturing facility….
Relief Therapeutics and its US partner, NeuroRx, Inc. recently announced that the Phase 2/3 clinical trial evaluating RLF-100 as a treatment for critical COVID-19 with…
FORMULATION FORUM – Application of Captisol® Technology to Enable the Formulation of Remdesivir in Treating COVID-19 June 4, 2020
James Pipkin, PhD, Vince Antle, PhD, and Rebecca Garcia-Fandiño, PhD, explain why more Captisol® than ever is required to meet Gilead’s bold goals of making remdesivir available to COVID-19 patients in the US and to hundreds of countries around the world.